In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.
Vaupel, A., Holzer, P., Ferretti, S., Guagnano, V., Kallen, J., Mah, R., Masuya, K., Ruetz, S., Rynn, C., Schlapbach, A., Stachyra, T., Stutz, S., Todorov, M., Jeay, S., Furet, P.(2018) Bioorg Med Chem Lett 28: 3404-3408
- PubMed: 30217415 
- DOI: 10.1016/j.bmcl.2018.08.027
- Primary Citation of Related Structures:  
6GGN - PubMed Abstract: 
Small molecule inhibitors of the p53-MDM2 protein complex are under intense investigation in clinical trials as anti-cancer agents, including our first generation inhibitor NVP-CGM097. We recently described the rational design of a novel pyrazolopyrr ...